On Friday, Wolfe Research initiated coverage on shares of Veracyte, Inc (NASDAQ:VCYT), a diagnostics company, with an Outperform rating and a price target of $50.00. The firm highlighted Veracyte's significant revenue growth and gross margin expansion since 2021. According to the research firm, Veracyte's revenue has doubled and its gross margin has increased by approximately 500 basis points.
The company is on track to achieve an adjusted EBITDA of $90-100 million for the current year. Wolfe Research noted that Veracyte has transitioned from a company with a strong product and solid science to a self-sustaining entity with a growth-oriented portfolio. The firm anticipates high single-digit to low double-digit revenue growth and expects EBITDA margins to approach 30% over the next five years.
Wolfe Research praised Veracyte's management, ranking it near the top in the lab diagnostics sector. This assessment is part of the firm's proprietary DOUGie Points system, which evaluates management performance among other factors.
The price target of $50.00 set by Wolfe Research is based on approximately 7 times the firm's 2026 revenue forecast and around 26 times its 2026 EBITDA forecast. These multiples are consistent with the valuation derived from Wolfe Research's discounted cash flow (DCF) analysis. When compared to its peers, Veracyte's adjusted EBITDA level stands out, and the sales multiple aligns with the current year enterprise value-to-sales valuation for the peer group.
In other recent news, Veracyte, Inc. has reported a significant 29% year-over-year increase in revenue, totaling $115.9 million for Q3 2024, driven by a strong performance in its testing business.
The company also raised its total revenue guidance for 2024 to between $442 million and $445 million, reflecting confidence in its growth and market expansion plans. In addition, Veracyte announced GAAP net income of $15.2 million, with an adjusted EBITDA of $27.3 million, or 24% of revenue.
Despite anticipating a $6 million revenue headwind due to the pause in the Envisia test, the company remains optimistic about its future growth, with plans to expand Decipher into the metastatic prostate cancer market and launch a MRD test for bladder cancer in 2026. Veracyte also expects to maintain strong cash reserves, with a year-end forecast of $280 million to $285 million.
These are among the recent developments that point to Veracyte's continued growth trajectory and market expansion in the diagnostic testing industry.
InvestingPro Insights
Veracyte's recent financial performance and market position align well with Wolfe Research's optimistic outlook. According to InvestingPro data, Veracyte's revenue growth remains strong, with a 23.95% increase over the last twelve months as of Q3 2024, and an even more impressive 28.58% quarterly growth in Q3 2024. This robust growth supports Wolfe Research's projection of high single-digit to low double-digit revenue growth in the coming years.
The company's transition to a self-sustaining entity is further evidenced by its solid balance sheet. An InvestingPro Tip highlights that Veracyte holds more cash than debt, indicating financial stability. Additionally, the company's liquid assets exceed short-term obligations, suggesting a strong liquidity position.
While Veracyte was not profitable over the last twelve months, InvestingPro Tips indicate that analysts expect the company to become profitable this year. This aligns with Wolfe Research's positive EBITDA projections and the company's improving financial metrics.
Investors should note that Veracyte's stock has shown significant momentum, with a 57.28% price return over the past six months. However, with a high EBIT valuation multiple, as pointed out by InvestingPro, the stock may be considered richly valued by some metrics.
For those interested in a deeper analysis, InvestingPro offers 12 additional tips for Veracyte, providing a comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.